wound model comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-20. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 0.9 kDa | Depends on exact fragment sequence and counterion |
| Amino acid sequence | LKKTETQ (commonly cited) | Short actin-binding motif from thymosin beta-4 |
| Common salt form | Acetate salt | Trifluoroacetate also reported in research material |
| Reconstitution solvent | Sterile water or buffer | Gentle mixing; avoid vigorous agitation |
| Solution storage | -20 °C or lower | Aliquot to avoid repeated freeze-thaw cycles |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
== Organizations == Macedonian Scientific Institute, an institution in Sofia, Bulgaria Marketing Science Institute, a nonprofit learning institution in Cambridge, Massachusetts, US Media Sport Investment, the international fund of investors that ran Sport Club Corinthians Paulista Millennium Science Initiative, an international program bringing technology to developing nations Ministry of Science and Innovation (New Zealand) Minority-serving institution, in US higher education MSI Reproductive Choices, an international non-governmental organisation providing contraception and safe abortion services, with a global HQ in London, UK Museum of Science and Industry (Chicago), US Science and Industry Museum, in Manchester, England University of Minnesota Supercomputing Institute Italian Social Movement (Movimento Sociale Italiano), a defunct post-fascist party
This text states that if "you don't get attracted, grasp, and commit to the notion 'my self', you'll have no doubt or uncertainty that what arises is just suffering arising, and what ceases is just suffering ceasing." Similarly, the Mahānidānasutta (DN 15) associates understanding dependent origination with abandoning various wrong views about a self, while failing to understand it is associated becoming entangled in these views. Another sutra, SĀ 297, states that dependent origination is "the Dharma Discourse on Great Emptiness", and then proceeds to refute numerous forms of "self-view" (ātmadṛṣṭi). SN 12:12 (parallel at SĀ 372) the Buddha is asked a series of questions about the self (who feels? who craves? etc.), the Buddha states that these questions are invalid, and instead teaches dependent origination. SĀ 80 also discusses an important meditative attainment called the emptiness concentration (śūnyatāsamādhi) which in this text is associated contemplating how phenomena arise due to conditions and are subject to cessation.
Mutations in the pore forming subunit of P type calcium channels cause ataxia, severely altered respiration, by decreasing minute ventilation and producing symptoms associated with atelectasis. Mutations to CaV2.1 have also been shown to affect transmission within the pre-Bötzinger Complex, a cluster of interneurons in the brainstem which help to regulate breathing.
During the period of the Rhodesian Bush War in the late 1960s and 1970s, the BSAP formed an important part of the white minority government's fight against Communist guerrillas. The force formed a riot unit; a tracker combat team (later renamed the Police Anti-Terrorist Unit or PATU); a police field force, Police Support Unit, (who were distinguished by wearing black boots), an Urban Emergency Unit, a Police Reserve Air Wing or PRAW, and a Marine Division. Many of its white personnel were national servicemen and conscripted reservists. At independence, the force had a strength of approximately 11,000 regulars (about 60% black) and almost 35,000 reservists, of whom the overwhelming majority were white. A former BSAP officer, Daniel Carney, wrote a book titled Whispering Death about the BSAP in anti-terrorist operations which was later made into the film Albino.
Sources: en.wikipedia.org
===== Uruguay ===== In December 2024, Lula visited Uruguay to attend a Mercosur summit that culminated in the signing of the EU–Mercosur Association Agreement. He also met with former Uruguayan former president José Mujica, whom he decorated with the Order of the Southern Cross, Brazil's highest award, and president-elect Yamandú Orsi.
=== Preclinical === AM-510 – undefined mechanism of action – opioid-related disorders ATI-1013 – monoclonal antibody against nicotine – smoking withdrawal CTRX-1001 – immunostimulant – opioid-related disorders CTRX-2001 – immunostimulant – opioid-related disorders Cyclobenzaprine (KRL-102; TNX-102; Tonmya; VLD-cyclobenzaprine) – tricyclic antidepressant (various actions) – alcoholism Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – cocaine-related disorders Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders Flumazenil/naloxone transdermal patch (MX-1607; RescuePatch) – combination of flumazenil (GABAA receptor negative allosteric modulator/benzodiazepine antagonist) and naloxone (opioid receptor antagonist) – substance-related disorders GM-3009 – κ-opioid receptor agonist (noribogaine analogue) – opioid-related disorders INDV-1000 (GABAB PAM) – GABAB receptor positive allosteric modulator – substance-related disorders KB-128 – serotonin 5-HT2C receptor G protein-biased agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist – alcoholism LPH-48 – undefined mechanism of action and serotonergic psychedelic ((shorter-acting LPH-5 analogue) – alcoholism M-101 – GABA receptor antagonist – substance-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – cocaine-related disorders Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – substance-related disorders Midomafetamine microneedle transdermal patch (MDMA; ecstasy) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, entactogen – substance-related disorders Naltrexone controlled-release (BICX101, BICX-101) – opioid receptor antagonist – alcoholism, opioid-related disorders Nicotine degrading enzyme (ATI-3009; NicA2; NicA2-J1) – enzyme – smoking withdrawal PPL-138 (BU10038, BU-10038) – nociceptin receptor agonist, μ-opioid receptor agonist, opioid peptide agonist – alcoholism, cocaine-related disorders PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders Psilacetin (O-acetylpsilocin; 4-AcO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – substance-related disorders Pudafensine (IP-2015; IP-2017; IPNP-2015; IPTN-2021) – serotonin–norepinephrine–dopamine reuptake inhibitor – substance-related disorders Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism of action and serotonergic psychedelics – alcoholism Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders SVN-015 – serotonin–dopamine reuptake inhibitor – substance-related disorders SXC-2023 – cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator – cocaine-related disorders, smoking withdrawal [15] [16] TACT411 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism TACT523 – undefined mechanism of action – alcoholism TACT833 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism VS-01 (VS-01-HAC) – ammonia scavenger – substance-related disorders
== Overdose and toxicity == The German Federal Institute for Risk Assessment warns that muscimol and products containing it pose serious health risks, especially to children. The toxicity and safety profile of muscimol has been studied in various contexts, both experimental and clinical. It is described as being a relatively toxic compound in animals. The median lethal dose (LD50) in mice is 5.6 to 7 mg/kg intravenously, 3.8 mg/kg subcutaneously, 2.5 to 12 mg/kg intraperitoneally, and 22 mg orally. The LD50 in rats is 4.5 mg/kg intravenously and 45 mg/kg orally. Muscimol shows considerably greater lethal potency or toxicity than gaboxadol. A study on non-human primates indicated that muscimol, when administered in escalating doses, caused reversible hyperkinesia and dyskinesias at higher doses, but no long-term toxicity was observed on histological examination. Muscimol has shown potential as an anticonvulsant, blocking seizures induced by various agents in animal models without causing significant toxicity at therapeutic doses. Muscimol exhibits dose-dependent effects with higher doses leading to significant, but reversible, central nervous system symptoms. The dose of muscimol that is thought to be potentially fatal in humans has been reported to be approximately 90 mg, which is 15 times the reported threshold hallucinogenic dose of 6 mg.
Sources: en.wikipedia.org
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.
Reversed-phase liquid chromatography separates components and reports purity from peak area. Mass spectrometry confirms the molecular mass expected for the sequence. Additional approaches such as peptide mapping or amino acid analysis provide independent confirmation.
Reported percentages depend on the analytical method, the detection wavelength, and whether salts and water are counted. A value above ninety-five percent by chromatography does not by itself establish a correct sequence. Different suppliers also calculate purity against different reference standards.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.